
New financing and clinical trial for RSV/hMOV bivalent vaccine
Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses. The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. The technology stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for… Read More















